Embelin suppresses pancreatic cancer growth by modulating tumor immune microenvironment.

@article{Marsh2014EmbelinSP,
  title={Embelin suppresses pancreatic cancer growth by modulating tumor immune microenvironment.},
  author={J Lawrence Marsh and Christopher P. Jackman and Su-Ni Tang and Sharmila Shankar and R. K Srivastava},
  journal={Frontiers in bioscience},
  year={2014},
  volume={19},
  pages={
          113-25
        },
  url={https://api.semanticscholar.org/CorpusID:34971852}
}
Data suggest that embelin can inhibit pancreatic cancer growth by modulating tumor immune microenvironment and Akt and Shh pathways, and inhibiting inflammation.
View on PubMed
imrpress.com
26 Citations
Background Citations
14

Figures from this paper

26 Citations

Embelin Suppresses Growth of Human Pancreatic Cancer Xenografts, and Pancreatic Cancer Cells Isolated from KrasG12D Mice by Inhibiting Akt and Sonic Hedgehog Pathways

The data suggest that embelin can inhibit pancreatic cancer growth, angiogenesis and metastasis by suppressing Akt and Shh pathways, and can be developed for the treatment and/or prevention of Pancreatic cancer.

Pancreatic Cancer Fostered Immunosuppression Privileges Tumor Growth and Progression

Of the several treatment strategies aiming to abolish the immune cell imbalance in PDAC, and targeting the immune system, DCs manipulation, vaccination with tumor derived antigens and Treg depletion appear to be of benefit, but still require validation before being recommended in the clinical setting.

Myeloid‐derived suppressor cells: Roles in the tumor microenvironment and tumor radiotherapy

The recent progress of MDSCs in roles of the tumor microenvironment and tumor radiotherapy is reviewed, with a focus on myeloid‐derived suppressor cells.

Targeting E-cadherin expression with small molecules for digestive cancer treatment.

Digestive system cancers, mainly including gastric cancer, hepatocellular carcinoma, pancreatic cancer, and colorectal cancer, are major public health problems and lead to serious cancer-related…

α-Mangostin-encapsulated PLGA nanoparticles inhibit pancreatic carcinogenesis by targeting cancer stem cells in human, and transgenic (KrasG12D, and KrasG12D/tp53R270H) mice

The data suggest that mangostin-encapsulated PLGA nanoparticles can inhibit pancreatic cancer growth, development and metastasis by targeting Shh pathway.

Embelin Inhibits Invasion and Migration of MDA‐MB‐231 Breast Cancer Cells by Suppression of CXC Chemokine Receptor 4, Matrix Metalloproteinases‐9/2, and Epithelial–Mesenchymal Transition

It is suggested that EB can abrogate breast cancer cell invasion and metastasis by suppression of CXCR4, MMP‐9/2 expressions, and inhibition of epithelial–mesenchymal transition and thus may have a great potential to suppress metastasis of breast cancer.

Targeted molecular ablation of cancer stem cells for curing gastrointestinal cancers

A novel approach to ablate CSCs in GI cancers, including esophageal, gastric, and colon cancers, is introduced along with explored underlying molecular mechanisms.

Embelin induces apoptosis of human gastric carcinoma through inhibition of p38 MAPK and NF-κB signaling pathways.

Treatment with embelin decreased cell proliferation, induced caspase‑3 activation and suppressed NF‑κB p65 activation in SGC7901 cells, and it was suggested that embelin may be used as a potential drug for the treatment of gastric carcinoma.

Inhibitory effect of Embelin on human acute T cell lymphoma Jurkat cells through activation of the apoptotic pathway.

Embelin inhibited growth and induced apoptosis of Jurkat cells in vitro, by activating the endogenous caspase-dependent apoptotic pathway through inhibition of XIAP and proapoptotic Bcl-2 family members.

Potential of gamma/delta T cells for solid tumor immunotherapy

A review on gamma-delta T cell therapy products and their corresponding clinical trials reveals that chimeric antigen receptor (CAR) gamma-delta T therapy holds promise as an approach with encouraging preclinical outcomes, but practical issues pertaining to manufacturing and clinical aspects need resolution and further research is required.

41 References

EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer.

The data suggest that EGCG inhibits pancreatic cancer growth, invasion, metastasis and angiogenesis, and thus could be used for the management of pancreatic cancers prevention and treatment.

Hedgehog Signaling Antagonist GDC-0449 (Vismodegib) Inhibits Pancreatic Cancer Stem Cell Characteristics: Molecular Mechanisms

GDC-0499 can be used for the management of pancreatic cancer by targeting pancreatic CSCs and activated Gli genes repress DRs and Fas expressions, up-regulate the expressions of Bcl-2 and PDGFRα and facilitate cell survival.

Targeting apoptosis pathways in pancreatic cancer.

Resveratrol Inhibits Pancreatic Cancer Stem Cell Characteristics in Human and KrasG12D Transgenic Mice by Inhibiting Pluripotency Maintaining Factors and Epithelial-Mesenchymal Transition

It is suggested that resveratrol can be used for the management of pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition.

Hedgehog signaling pathway regulates human pancreatic cancer cell proliferation and metastasis.

Results indicate that activation of the Hh pathway is a common event and may be a potential target of new therapeutic strategies for pancreatic cancer, as well as inhibiting EMT, which is involved in early metastasis.

Sonic Hedgehog Signaling Inhibition Provides Opportunities for Targeted Therapy by Sulforaphane in Regulating Pancreatic Cancer Stem Cell Self-Renewal

It is proposed that pancreatic cancer preventative effects of SFN may result from inhibition of the Shh pathway, and Sulforaphane potentially represents an inexpensive, safe and effective alternative for the management of Pancreatic cancer.

Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells.

Sulforaphane either alone or in combination with quercetin can eliminate cancer stem cell-characteristics, suggesting the blockade of signaling involved in early metastasis.

Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment.

Current knowledge on the secretory properties of epithelial tumor cells that have undergone an EMT are summarized, with an emphasis on the potential role of the IL-8-IL-8 receptor axis on the induction and/or maintenance of tumor EMT and its ability to remodel the tumor microenvironment.

Pancreatic cancer: understanding and overcoming chemoresistance

Selective and targeted elimination of cells with an EMT phenotype and cancer stem cells could be achieved by regulating the expression of specific miRNAs, which seem to be critical regulators of drug resistance in pancreatic cancer cells.

Embelin suppresses STAT3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase PTEN.